本文针对CREST-2试验引发的临床争议，深入探讨无症状颈动脉狭窄治疗策略的演变。研究团队通过对比最佳药物治疗（BMT）与血 ...

MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, welcomes the recent ...

Adding stenting to intensive medical therapy significantly improves outcomes among patients with asymptomatic high-grade carotid stenosis compared with drug treatment alone, a bar not met by carotid ...

TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today ...

CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) ...